pf-06840003
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 9, 2016 (NCT02764151)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Indoleamine 2,3-dioxygenaseINHIBITOR
IDO1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C1CC(c2c[nH]c3ccc(F)cc23)C(=O)N1- Mol. weight
- 232.21 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4086143 ↗
Also known as
- pf-06840003
- pf-06840003
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02764151 | Phase 1 | Sep 9, 2016 | Pfizer |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 1 | 1 | 1 | 2016 |
1 organizations
Page 1 / 1